CAELIMIR
DEAD

Serial Number

79406277

Owner

ToxGenSolutions BV

Filing Date

Aug 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CAELIMIR Trademark

Serial Number: 79406277

CAELIMIR is a trademark filed by ToxGenSolutions BV on August 8, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

ToxGenSolutions BV

Oxfordlaan 70

Entity Type: 26

Trademark Details

Filing Date

August 8, 2024

Registration Date

Not Registered

Goods & Services

Software relating to the pharmaceutical field; bioinformatics software; healthcare software; software relating to the medical field; software relating to research, discovery and development of pharmaceuticals, therapeutics and/or diagnostics; electronic databases for capturing, storing, processing, evaluating and reproducing pharmaceutical data; all of the aforementioned goods whether or not including artificial intelligence.

Providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing pharmaceutical data; software as a service (SaaS) featuring health monitoring software; software as a service (SaaS) featuring bioinformatics software; scientific computer programming services; pharmaceutical research and development; research and development of mRNA-based therapeutics; research and development of mRNA-based diagnostics; research and development of mRNA drugs; research and development in the field of microorganisms and cells; pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; development of gene-based medicines; laboratory research services relating to pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; services for assessing the efficiency of pharmaceuticals; information technology services for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; chemical research and analysis services; medical and pharmacological research services; scientific research for medical purposes; research and development in the field of diagnostic preparations; genetic research; genetic mapping for scientific purposes; providing scientific information in the field of medical disorders and their treatment; biotechnological research; biochemical research and development; research and development of vaccines; pharmaceutical drug discovery and development services; all of the aforementioned services whether or not including artificial intelligence; platform as a Service (PaaS), Software as a Service (SaaS) and/or Data as a Service (DaaS) in relation to all the aforementioned services.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 9, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 9, 2026 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Nov 14, 2025 NREP
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Oct 10, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 10, 2025 ABN2
REFUSAL PROCESSED BY IB
Apr 12, 2025 RFNT
NEW REPRESENTATIVE AT IB RECEIVED
Mar 28, 2025 NREP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 25, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 25, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 19, 2025 RFCR
NON-FINAL ACTION WRITTEN
Feb 19, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 13, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 11, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 11, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 10, 2024 REPR